The manufacturing process should remain the focus for severe febrile reactions in children administered an Australian inactivated influenza vaccine during 2010

Influenza and other Respiratory Viruses

Volumn 10, Issue 1, 2016, Pages 9-13

  Li Kim Moy, Jean ^a,b   Booy, Robert ^a,b,c  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c University of Sydney   (Australia)

Author keywords

CSL; Adverse events; Febrile seizures; Fever; Influenza vaccine; Safety

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUSTRALIA; CHILD; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DRUG SAFETY; FEBRILE CONVULSION; FEVER; GOOD MANUFACTURING PRACTICE; HUMAN; IMMUNOGENICITY; INFLUENZA A VIRUS (H1N1); INFLUENZA VACCINATION; NONHUMAN; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS STRAIN; BIOSYNTHESIS; CHEMICALLY INDUCED; HEK293 CELL LINE; INFANT; PATIENT SAFETY; POSTMARKETING SURVEILLANCE; PRESCHOOL CHILD;

AUSTRALIA; CHILD, PRESCHOOL; HEK293 CELLS; HUMANS; INFANT; INFLUENZA VACCINES; PATIENT SAFETY; PRODUCT SURVEILLANCE, POSTMARKETING; SEIZURES, FEBRILE;

EID: 84954538229     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12337     Document Type: Article

References (25)

1. Skowronski DM, Strauss B, De Serres G et al. Oculo-respiratory syndrome: a new influenza vaccine-associated adverse event? Clin Infect Dis 2003; 36:705-713.
2. Miller E, Andrews N, Stellitano L et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013; 346:f794.
3. Rockman S, Dyson A, Koernig S et al. Evaluation of the bioactivity of influenza vaccine strains in vitro suggests that the introduction of new strains in the 2010 Southern Hemisphere Trivalent Influenza Vaccine is associated with adverse events. Vaccine 2014; 32:3861-3868.
4. Therapeutic Goods Administration. Overview of vaccine regulation and safety monitoring and investigation into adverse events following 2010 seasonal influenza vaccination in young children. 2010. Available at https://www.tga.gov.au/file/555/download (Accessed 11 September 2012).
5. Centers for Disease Control and Prevention. ACIP recommendation for use of CSL influenza vaccine. 2010. Available at http://www.cdc.gov/media/pressrel/2010/s100806.htm (Accessed 16 February 2015).
6. Therapeutic Goods Administration. Seasonal influenza vaccines: safety advisory. 2011. Available at https://www.tga.gov.au/alert/seasonal-influenza-vaccines (Accessed 15 February 2015).
7. Armstrong PK, Dowse GK, Effler PV et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open 2011; 1:e000016.
8. Petousis-Harris H, Poole T, Turner N, Reynolds G. Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: the importance of routine active safety surveillance. Vaccine 2012; 30:4945-4952.
9. Blyth CC, Currie AJ, Wiertsema SP et al. Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms. Vaccine 2011; 29:5107-5113.
10. Blyth CC, Richmond PC, Jacoby P et al. The impact of pandemic A(H1N1)pdm09 influenza and vaccine-associated adverse events on parental attitudes and influenza vaccine uptake in young children. Vaccine 2014; 32:4075-4081.
11. Maraskovsky E, Rockman S, Dyson A et al. Scientific investigations into febrile reactions observed in the paediatric population following vaccination with a 2010 Southern Hemisphere Trivalent Influenza Vaccine. Vaccine 2012; 30:7400-7406.
12. Rockman S, Becher D, Dyson A et al. Role of viral RNA and lipid in the adverse events associated with the 2010 Southern Hemisphere trivalent influenza vaccine. Vaccine 2014; 32:3869-3876.
13. Vaccine adverse event reporting system (VAERS). Available at https://vaers.hhs.gov/index (Accessed 9 July 2015).
14. Nolan T, Richmond PC, McVernon J et al. Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children. Influenza Other Respir Viruses 2009; 3:315-325.
15. Lambert S, Chuk L, Nissen M et al. Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children, and adolescents. Influenza Other Respir Viruses 2013; 7:676-685.
16. Li-Kim-Moy J, Yin JK, Rashid H et al. Systematic review of fever, febrile convulsions and serious adverse events following administration of inactivated trivalent influenza vaccines in children. Eurosurveillance 2015; 20: pii=21159.
17. Wood N, Sheppeard V, Cashman P et al. Influenza vaccine safety in children less than 5 years old: the 2010 and 2011 experience in Australia. Pediatr Infect Dis J 2012; 31:199-202.
18. Kaczmarek MC, Duong UT, Ware RS, Lambert SB, Kelly HA. The risk of fever following one dose of trivalent inactivated influenza vaccine in children aged ≥6 months to <36 months: a comparison of published and unpublished studies. Vaccine 2013; 31:5359-5365.
19. Wood NJ, Blyth CC, Willis GA et al. The safety of seasonal influenza vaccines in Australian children in 2013. Med J Aust 2014; 201:596-600.
20. Brady RC, Hu W, Houchin VG et al. Randomized trial to compare the safety and immunogenicity of CSL Limited's 2009 trivalent inactivated influenza vaccine to an established vaccine in United States children. Vaccine 2014; 32:7141-7147.
21. Kelly HA, Skowronski DM, De Serres G, Effler PV. Adverse events associated with 2010 CSL and other inactivated influenza vaccines. Med J Aust 2011; 195:318-320.
22. Centers for Disease Control and Prevention, Epidemiology and Prevention of Vaccine-Preventable Diseases. Vaccine excipient and media summary, by vaccine. Epidemiology and Prevention of Vaccine-Preventable Diseases [Internet]. Washington, DC: Public Health Foundation, 2015. Available at http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf (Accessed 22 July 2015).
23. bioCSL PTY LTD. A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 years to <9 years. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US), 2000; Available at https://clinicaltrials.gov/ct2/show/NCT02212106?term=NCT02212106 NLM Identifier: NCT02212106 (Accessed 22 July 2015).
24. ClinicalStudyDataRequest.com. Available at www.clinicalstudydatarequest.com (Accessed 10 August 2014).
25. CSL Limited. CSL to acquire Novartis' influenza vaccine business. Available at http://www.biocsl.com.au/docs/107/931/CSL-Media-release_Novartis-Acquistion, 0.pdf (Accessed 27 October 2014).